We serve Chemical Name:2-Ethyl-4,5-dimethyloxazole CAS:53833-30-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Ethyl-4,5-dimethyloxazole
CAS.NO:53833-30-0
Synonyms:EINECS 258-815-4;2-ethyl-4,5-dimethyl-1,3-oxazole
Molecular Formula:C7H11NO
Molecular Weight:125.16800
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:166.4ºC at 760 mmHg
Density:0.956 g/cm3
Index of Refraction:1.46
PSA:26.03000
Exact Mass:125.08400
LogP:1.85380
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like EINECS 258-815-4 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-ethyl-4,5-dimethyl-1,3-oxazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-ethyl-4,5-dimethyl-1,3-oxazole Use and application,EINECS 258-815-4 technical grade,usp/ep/jp grade.
Related News: The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement. 2-Ethyl-4,5-dimethyloxazole manufacturer The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement. 2-Ethyl-4,5-dimethyloxazole supplier ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment��s chemistry, manufacturing and controls process, but not its safety. 2-Ethyl-4,5-dimethyloxazole vendor Drug manufacturers make medicines by mixing APIs and pharmaceutical excipients. 2-Ethyl-4,5-dimethyloxazole factory ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment��s chemistry, manufacturing and controls process, but not its safety.
